Hyperprogression fortgeschrittener Melanomerkrankung unter Pembrolizumab adjuvant
Standard
Hyperprogression fortgeschrittener Melanomerkrankung unter Pembrolizumab adjuvant. / Geidel, Glenn; Ammann, Nadine L; Schneider, Stefan W; Gebhardt, Christoffer.
In: J DTSCH DERMATOL GES, Vol. 19, No. S1, 07.2021, p. 37-39.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
Geidel, G, Ammann, NL, Schneider, SW & Gebhardt, C 2021, 'Hyperprogression fortgeschrittener Melanomerkrankung unter Pembrolizumab adjuvant', J DTSCH DERMATOL GES, vol. 19, no. S1, pp. 37-39. https://doi.org/10.1111/ddg.14480
APA
Geidel, G., Ammann, N. L., Schneider, S. W., & Gebhardt, C. (2021). Hyperprogression fortgeschrittener Melanomerkrankung unter Pembrolizumab adjuvant. J DTSCH DERMATOL GES, 19(S1), 37-39. https://doi.org/10.1111/ddg.14480
Vancouver
Geidel G, Ammann NL, Schneider SW, Gebhardt C. Hyperprogression fortgeschrittener Melanomerkrankung unter Pembrolizumab adjuvant. J DTSCH DERMATOL GES. 2021 Jul;19(S1):37-39. https://doi.org/10.1111/ddg.14480
Bibtex
@article{89e9570d7eba4dda9d002745e6edd19a,
title = "Hyperprogression fortgeschrittener Melanomerkrankung unter Pembrolizumab adjuvant",
author = "Glenn Geidel and Ammann, {Nadine L} and Schneider, {Stefan W} and Christoffer Gebhardt",
year = "2021",
month = jul,
doi = "10.1111/ddg.14480",
language = "English",
volume = "19",
pages = "37--39",
journal = "J DTSCH DERMATOL GES",
issn = "1610-0379",
publisher = "Wiley-Blackwell",
number = "S1",
}
RIS
TY - JOUR
T1 - Hyperprogression fortgeschrittener Melanomerkrankung unter Pembrolizumab adjuvant
AU - Geidel, Glenn
AU - Ammann, Nadine L
AU - Schneider, Stefan W
AU - Gebhardt, Christoffer
PY - 2021/7
Y1 - 2021/7
U2 - 10.1111/ddg.14480
DO - 10.1111/ddg.14480
M3 - SCORING: Journal article
C2 - 33835653
VL - 19
SP - 37
EP - 39
JO - J DTSCH DERMATOL GES
JF - J DTSCH DERMATOL GES
SN - 1610-0379
IS - S1
ER -
